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Epigenetic deregulation of GATA3 
in neuroblastoma is associated 
with increased GATA3 protein 
expression and with poor outcomes
Bader Almutairi1,3, Jessica charlet1,4, Anthony R. Dallosso  1,5, Marianna Szemes1, 
Heather C. etchevers  2, Karim T. A. Malik1 & Keith W. Brown  1*
To discover epigenetic changes that may underly neuroblastoma pathogenesis, we identified 
differentially methylated genes in neuroblastoma cells compared to neural crest cells, the presumptive 
precursors cells for neuroblastoma, by using genome-wide DNA methylation analysis. We previously 
described genes that were hypermethylated in neuroblastoma; in this paper we report on 67 
hypomethylated genes, which were filtered to select genes that showed transcriptional over-expression 
and an association with poor prognosis in neuroblastoma, highlighting GATA3 for detailed studies. 
Specific methylation assays confirmed the hypomethylation of GATA3 in neuroblastoma, which 
correlated with high expression at both the RNA and protein level. Demethylation with azacytidine 
in cultured sympathetic ganglia cells led to increased GATA3 expression, suggesting a mechanistic 
link between GATA3 expression and DNA methylation. Neuroblastomas that had completely absent 
GATA3 methylation and/or very high levels of protein expression, were associated with poor prognosis. 
Knock-down of GATA3 in neuroblastoma cells lines inhibited cell proliferation and increased apoptosis 
but had no effect on cellular differentiation. These results identify GATA3 as an epigenetically regulated 
component of the neuroblastoma transcriptional control network, that is essential for neuroblastoma 
proliferation. This suggests that the GATA3 transcriptional network is a promising target for novel 
neuroblastoma therapies.
Neuroblastoma (NB) is one of the commonest extra-cranial solid malignancies of childhood, which arises as a 
result of disordered development of the sympathetic nervous system from neural crest cells1,2. Neuroblastoma is 
clinically heterogeneous, with younger patients (<18months) generally having localised tumours and good out-
comes, whereas older children (>18months) mostly have disseminated tumours at diagnosis and poor outcomes3.
The clinical heterogeneity of neuroblastoma is reflected in its molecular pathogenesis, where no single path-
way has been identified as being critical for tumour development. Oncogene activations were the first genetic 
alterations identified in neuroblastoma; initially MYCN amplification was identified in high-risk tumours4 
and later ALK mutations were discovered in inherited neuroblastoma and some sporadic high-risk tumours5,6. 
Mutations in tumour suppressor genes such as PHOX2B7 and NF18 have also been reported. Recent genome-wide 
analyses have identified genomic mutations and other alterations in chromatin remodelling genes such as ATRX, 
ARID1A and ARID1B, in components of the RAC-RHO pathway9–11 and in TERT12,13, with relapsed tumours 
demonstrating an increased mutation rate14,15.
Like most childhood cancers, neuroblastomas contain fewer mutations than adult cancers16,17, with some 
tumours apparently containing no detectable driver mutations9–11. In low-risk neuroblastomas, copy-number 
changes may drive tumorigenesis18, but the lack of driver mutations in many cases, emphasises the need to con-
sider other mechanisms of pathogenesis, such as epigenetic alterations19.
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Epigenetic changes have been shown to play an important role in neuroblastoma, with well-characterised 
examples of silencing of tumour suppressor genes by DNA methylation20–24, or by repressive histone modifica-
tions24–26. Recent genome-wide studies have characterised widespread alterations in DNA methylation in neuro-
blastoma24,27–34, confirming previous associations between a hypermethylator phenotype and poor prognosis, as 
well as identifying subgroup-specific epigenetic profiles35.
In order to identify epigenetic changes associated with the development of neuroblastoma, we previously used 
genome-wide DNA methylation analysis to compare neuroblastoma cells to neural crest cells, their cellular pre-
cursors, and identified MEGF10 as an epigenetically repressed putative tumour suppressor gene24. Interestingly, 
like other recent studies31,32, we found a preponderance of hypomethylated genes, suggesting that epigenetic 
activation of normally silenced genes in neural crest cells is critical in neuroblastoma pathogenesis. In this paper 
we have therefore investigated the hypomethylated genes identified in our previous work24, demonstrating 
that GATA3, a transcription factor known to be critical in development of the sympathetic nervous system36–38 
and a gene often dysregulated in diverse human cancers39, is frequently affected by epigenetic deregulation in 
neuroblastoma.
Results
Hypomethylated genes in neuroblastoma. We have previously described our genome-wide analysis of 
DNA methylation in neuroblastoma, in which we used methyl CpG immunoprecipitation (MCIP) and promoter 
microarrays, to compare neuroblastoma cell lines with human neural crest cells (hNCC)24. In our previous paper, 
we described our results on genes that were hypermethylated in neuroblastoma compared to hNCC24; in this 
paper we discuss hypomethylated genes.
A total of 67 genes were found by MCIP to be hypomethylated in neuroblastoma cell lines compared to hNCC 
(Fig. 1 and Supplementary Table S1). Gene ontology analysis showed this group to be enriched in genes regulating 
biological processes, G-protein coupled receptor signalling and sensory perception (Supplementary Table S2). 
To filter the hypomethylated genes for those likely to be functionally important in neuroblastoma pathogenesis, 
we used publicly available databases to search for genes that; (1) were overexpressed in neuroblastoma cell lines 
and tumour tissue compared to hNCC (reasoning that hypomethylated genes would be expected to have elevated 
expression) and (2) showed an association of high gene expression in tumours with poorer patient survival (to 
identify genes affecting neuroblastoma biological properties). Six genes had both the required over-expression 
and association with poor patient survival, but only one, GATA3, had a high CpG-content CpG island (CGI), sug-
gesting it might be most susceptible to epigenetic deregulation (Fig. 1 and Supplementary Table S1). In addition, 
GATA3 was known to be of importance in development of sympathetic nervous tissue, from which neuroblas-
toma derives1,2. We therefore went on to examine the DNA methylation, expression and functional relevance of 
GATA3 in neuroblastoma.
GATA3 methylation in neuroblastoma. Examination of the MCIP data showed that the major area of 
hypomethylation in neuroblastoma cell lines compared to hNCC, centred on the start of the GATA3 antisense 
transcripts in the CGI (Fig. 2A). We used two commercially-available pyrosequencing assays to examine DNA 
methylation in this region (Fig. 2A) and found that neuroblastoma cell lines and tumour tissue were significantly 
hypomethylated compared to a panel of control tissues, consisting of hNCC, fetal adrenal tissue (FA) and dorsal 
root ganglia/sympathetic ganglia cell lines (DRG/SG) (Fig. 2B,C).
We extracted GATA3 DNA methylation data from the publicly available dataset GSE54719, which confirmed 
hypomethylation across the start of the GATA3 antisense transcripts in neuroblastoma tumours, compared to 
adrenal tissue (Supplementary Fig. S1).
Using survival data available for our patient cohort, we demonstrated that complete absence of DNA methyla-
tion within the hypomethylated region was associated with worse relapse-free survival and worse overall survival 
in neuroblastoma patients (Fig. 2D,E).
These results suggested that epigenetic deregulation of GATA3 by altered DNA methylation might be func-
tionally important in neuroblastoma. We therefore investigated whether DNA methylation affected GATA3 
expression in neuroblastoma.
Relationship between GATA3 methylation and expression. In almost all neuroblastoma cell lines, 
there was little or no GATA3 DNA methylation, and much higher levels of expression of both the sense and 
antisense GATA3 RNAs, compared to normal tissues (FA, hNCC and DRG/SG), which had 7–22% DNA methyl-
ation, and very low RNA expression (Fig. 3A). The exceptions were SH-EP and GI-ME-N, S-type neuroblastoma 
cell lines (Supplementary Table S3), which had some GATA3 methylation and low RNA expression (Fig. 3A). In 
general, GATA3 sense and antisense RNA levels correlated positively, with N-type neuroblastoma cells generally 
having the highest antisense expression (Fig. 3A and Supplementary Fig. S2C). There was an inverse correlation 
between GATA3 DNA methylation and RNA expression in normal and neuroblastoma cell lines (Supplementary 
Fig. S2A,B).
GATA3 protein was overexpressed in nearly all neuroblastoma cell lines compared to normal tissue (Fig. 3B). 
The S-type cell line GI-ME-N had undetectable GATA3 protein and SH-EP had one of the lowest levels of expres-
sion (Fig. 3B), which agrees with the low levels of GATA3 RNA expression detected in these two S-type cell lines 
(Fig. 3A). Overall, there was a good correlation between GATA3 RNA and protein expression in the neuroblas-
toma cell lines (Supplementary Fig. S2D).
These findings suggested a possible relationship between GATA3 DNA methylation and expression, which 
we tested by treating DRG/SG cells with the DNA methylation inhibitor 5-aza-2′-deoxycytidine (AZA). AZA 
treatment resulted in a five-fold increase in GATA3 RNA expression, as well as increased expression of GATA3 
protein (Fig. 3C,D), implying that DNA methylation plays a mechanistic role in regulating GATA3 expression in 
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Figure 1. Hypomethylated genes in neuroblastoma. Genes identified by MCIP as hypomethylated in four 
neuroblastoma cell lines compared to hNCC. The first five columns (“Gene methylation”) are a heatmap of 
gene methylation values (blue = low, red = high). CGI (CpG island) properties: PRC shows genes that are 
polycomb marked in ES cells, LCP, ICP and HCP define which promoter CGIs have low, intermediate or high 
CpG content. For quantitative DNA methylation results and further explanation of PRC, LCP, ICP and HCP, 
see Table S1. NB data: “Survival” shows genes whose increased expression is significantly associated with 
reduced relapse-free survival in neuroblastoma (p < 0.05, log rank test); data generated in R2 using GSE16476. 
“Expression” shows genes whose RNA expression is increased in both neuroblastoma cell lines (GSE28019) 
and neuroblastoma tumours (GSE16476) compared to neural crest cells (GSE14340); comparison was made 
using the “Megasampler” function in R2 Genomics Analysis and Visualization Platform (http://r2.amc.nl). See 
Table S1 for full results.
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Figure 2. GATA3 DNA methylation in neuroblastoma. (A) GATA3 DNA methylation detected by MCIP. Black 
bars show the probe ratios derived from MCIP for hNCC and four neuroblastoma cell lines, positioned on 
the GATA3 CpG island promoter region, showing the sense and antisense transcripts and CpG island (CGI) 
(human genome build NCBI36/Hg18 visualised on the UCSC genome browser; http://genome.ucsc.edu). The 
positions of the hypomethylated region and the two pyrosequencing assays (01 and 02) are shown in red at the 
top. (B) Dotboxplot of GATA3 antisense DNA methylation measured by pyrosequencing in normal tissues (NT, 
n = 4), neuroblastoma cell lines (Cell lines, n = 12), and neuroblastoma tumour tissue (NB tissue, n = 24), using 
the average of pyrosequencing assays 01 and 02; full results in C; *p < 0.05, **p < 0.005, Bonferroni corrected 
Mann-Whitney test. (C) DNA methylation in the GATA3 antisense region in normal tissues (NT), NB cell lines 
(Cell lines) and NB tumour tissue (NB tissue), using pyrosequencing assays 01 (unfilled bars) and 02 (filled 
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sympathetic nervous system-derived cells. We then proceeded to investigate GATA3 RNA and protein expression 
in neuroblastoma tumour tissues from different stages, to search for any relationship between in vivo biological 
properties of tumours and GATA3 expression.
GATA3 RNA and protein expression in neuroblastoma. GATA3 sense RNA expression was signifi-
cantly elevated in neuroblastoma cell lines and tumours compared to normal tissues (FA, hNCC and DRG/SG; 
Fig. 4A,B). These results were replicated in publicly available gene expression data (Supplementary Fig. S3A), 
which also showed that high GATA3 RNA expression was associated with poor overall survival in neuroblastoma 
(Supplementary Fig. S3B).
Almost all neuroblastoma tumours expressed detectable GATA3 protein, of which 61% expressed higher levels 
than FA (Fig. 4C,D). In those tumours for which survival data were available, relapse-free survival and overall 
survival were both worse in patients whose tumours expressed more GATA3 protein than FA (Fig. 4E,F).
These results suggested that expression levels of GATA3 were correlated with the clinical properties of neu-
roblastoma tumours, so we examined GATA3 effects on cell proliferation and death, which could provide an 
explanation for these correlations.
Effects of GATA3 silencing in neuroblastoma cell lines. IMR32, Kelly and NGP neuroblastoma cell 
lines, all of which expressed high levels of GATA3 sense RNA and GATA3 protein (Fig. 3A,B), were transfected 
with siRNAs to knock-down GATA3 expression, and then cell proliferation and cell death were assessed by a 
variety of assays (Fig. 5, Supplementary Fig. S4). In all cell lines, the GATA3 siRNAs were effective in down regu-
lating both GATA3 RNA expression and GATA3 protein expression (Fig. 5A,B, Supplementary Fig. S4A,B,F,G). 
GATA3 knock-down inhibited cell proliferation (Fig. 5C, Supplementary Fig. S4C,H) and increased the number 
of dead cells in the cultures (Fig. 5D, Supplementary Fig. S4D,I). Cleaved PARP (c-PARP) protein levels increased 
in GATA3 siRNA-treated cells (Fig. 5A, Supplementary Fig. S4A,F), and this increase was abrogated by treating 
cells with the caspase inhibitor quinolyl-valyl-O-methylaspartyl-[2,6-difluorophenoxy]-methyl ketone (QVD) 
(Fig. 5E, Supplementary Fig. S4E,J). QVD treatment also abrogated the increased dead cell counts after GATA3 
knock-down (Fig. 5D, Supplementary Fig. S4D,I), which together with PARP cleavage, showed that the cell death 
was caused by caspase-mediated apoptosis.
To further investigate the possible pathways by which GATA3 influences neuroblastoma proliferation, we 
examined cyclin D1 (CCND1), one of the known targets of GATA3 that is involved in cell cycle regulation40. 
Flow cytometry demonstrated that in almost all GATA3 siRNA knock-downs, there was a reduced proportion of 
cells in G2-M, consistent with disrupted cell cycle control (Supplementary Fig. S5). Knock-down of GATA3 in 
neuroblastoma cell lines reduced CCND1 protein and RNA expression substantially (Fig. 5A,B, Supplementary 
Fig. S4A,B,F,G). In neuroblastoma tumours, most showed increased expression of CCND1 compared to FA, 
where it was undetectable (Supplementary Fig. S6A) and there was a good correlation between GATA3 protein 
expression and CCND1 protein expression (Supplementary Fig. S6B). This suggested that one of major mecha-
nisms by which GATA3 affects neuroblastoma cell proliferation may be via modulating CCND1 levels.
To assess whether GATA3 knock-down might be affecting cellular differentiation, we investigated the expres-
sion of a range of differentiation markers in the siRNA-transfected neuroblastoma cell lines (Supplementary 
Fig. S7). We assayed markers of both mesenchymal differentiation (VIM, PRRX1 and SNAI1) and adrenergic 
differentiation (NCAM, NF68), but observed no reproducible changes in gene expression, suggesting that GATA3 
knock-down only affects proliferation and death, but not differentiation, in neuroblastoma cells.
Discussion
In this paper we have examined genes that were hypomethylated in neuroblastoma, as identified by our previ-
ous genome-wide analysis of DNA methylation, comparing hNCC to neuroblastoma cell lines24. We have now 
shown that GATA3, an important regulator of sympathetic nervous system development36–38, is hypomethylated 
in neuroblastoma cell lines and tumour tissues (Figs. 2B,C, 3A and Supplementary Fig. S1). Hypomethylation of 
GATA3 correlated with upregulated expression of both GATA3 RNA and GATA3 protein (Figs. 3A,B, 4A–D and 
Supplementary Fig. S3).
These results suggest that the development of neuroblastoma from neural crest derivatives involves a change 
in the epigenetic state of GATA3, that is controlled at least partially by DNA methylation, which is known to be an 
important factor in neural crest development41. Interestingly, we found a maximum of 22% GATA3 DNA methyl-
ation in the normal tissues that we examined (Figs. 2C and 3A), suggesting that only a subpopulation of these cells 
have DNA methylated at GATA3, which could reflect an intrinsic heterogeneity in the neural crest population42.
The inverse correlation between GATA3 DNA methylation and RNA expression (Fig. 3A and Supplementary 
Fig. S2A,B), implied a functional role for DNA methylation in the repression of GATA3 transcription, which 
was supported by the increase in GATA3 expression following AZA treatment of DRG/SG cells (Fig. 3C,D). 
The five-fold increase in GATA3 RNA expression was perhaps surprising, considering the relatively low levels 
of GATA3 DNA methylation in DRG/SG cells (Fig. 2C). This could suggest that there is a small subpopula-
tion of methylated cells, which show greatly elevated GATA3 expression when they become demethylated, or 
bars). The genomic positions of assays 01 and 02 are shown in part A. (D,E) Kaplan–Meier survival curves (D, 
relapse-free survival; E, overall survival) taken from the dataset of NB patients in B and C for whom survival 
data were available. Me-, tumours with no GATA3 DNA methylation; Me + tumours with DNA methylation 
(using the average of pyrosequencing assays 01 and 02). p values from log-rank test.
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alternatively that the transcriptional regulation of GATA3 may be via another epigenetically regulated factor, 
rather than by a direct epigenetic effect on GATA3 itself.
Others have reported DNA methylation at the GATA3 CGI in breast cancer43,44 bladder cancer45 and some 
leukaemias46, with direct evidence that DNA methylation regulates GATA3 expression46,47. In our results, GATA3 
methylation was confined to the start of the GATA3 antisense transcript (Fig. 2A), although AZA treatment 
upregulated GATA3 sense RNA and GATA3 protein in methylated DRG/SG cells (Fig. 3C,D), suggesting a pos-
sible role for the antisense RNA in regulating GATA3 sense expression. We found a good correlation between 
GATA3 sense and antisense expression (Supplementary Fig. S2C), in agreement with a previous report48. That 
report suggested that the proximity of the transcriptional start sites of the GATA3 sense and antisense RNAs could 
imply the presence of a bidirectional promoter48. However, it has recently been shown that the GATA3 antisense 
RNA can bring MLL to the GATA3 promoter, to increase permissive chromatin marks and thus directly upregu-
late GATA3 expression49. Thus, it is likely that demethylation of GATA3 in neuroblastoma has an indirect effect, 
by increasing GATA3 antisense expression, which in turn attracts positive epigenetic regulators to the GATA3 
promoter region.
Our siRNA experiments demonstrated that knock-down of GATA3 expression reduced cell proliferation and 
increased apoptosis in neuroblastoma cell lines (Fig. 5, Supplementary Fig. S4). These results agree with previous 
Figure 3. GATA3 DNA methylation and expression. (A) GATA3 sense (hatched bars) and antisense (unfilled 
bars) RNA expression assayed by QPCR, and DNA methylation levels (black bars) detected by pyrosequencing, 
in control tissues and neuroblastoma cell lines. RNA levels were normalized to endogenous levels of TBP and 
expressed relative to hNCC. DNA methylation was calculated as the average of the 01 and 02 pyrosequencing 
assays. (B) GATA3 protein levels assayed by Western blot in normal tissues (NT) and type-S, type-I, I + S 
and type-N neuroblastoma cell lines, with ACTIN as a loading control. Uncropped blots are shown in 
Supplementary Fig. S10. (C) GATA3 sense RNA expression in DRG/SG cells treated with 2 μM AZA for 6 
days. RNA levels were normalized to endogenous levels of TBP and expressed relative to control. Mean ± 
S.E.M of three experiments; *p < 0.05, paired t test. (D) Western Blot of GATA3 protein expression in in DRG/
SG cells treated with 2 μM AZA for 6 days, with ACTIN as a loading control. Uncropped blots are shown in 
Supplementary Fig. S10.
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studies that have shown an essential role for GATA3 in the proliferation of neuroblastoma cells in vitro and for 
tumorigenicity in vivo50,51. We found that knock-down of GATA3 decreased CCND1 expression in neuroblas-
toma cell lines (Fig. 5, Supplementary Fig. S4) and that in tumour samples, there was high expression of CCND1 
compared to FA and a good correlation between GATA3 and CCND1 expression (Supplementary Fig. S6), as 
found by others40,52,53. Thus, one of the likeliest mechanisms by which GATA3 affects cell proliferation in neu-
roblastoma, is via regulation of its transcriptional target cyclin CCND140,54, which when knocked-down, shows 
similar effects on cell proliferation to GATA353. Given that we observed no effects on cellular differentiation 
Figure 4. GATA3 RNA and protein expression in neuroblastoma. (A) Dotboxplot of GATA3 sense RNA 
expression assayed by QPCR in normal tissues (NT, n = 3), neuroblastoma cell lines (Cell lines, n = 13),  
and neuroblastoma tumour tissue (NB tissue, n = 22). RNA levels were normalized to endogenous levels of  
TBP and expressed relative to hNCC; full results in B; *p < 0.05, Bonferroni corrected Mann-Whitney test.  
(B) Individual GATA3 RNA expression by QPCR. (C) GATA3 protein levels assayed by Western blot in stage 
1, 2, 3, 4 and 4S neuroblastoma tumour tissue, with ACTIN as a loading control. Uncropped blots are shown in 
Supplementary Fig. S11. (D) GATA3 protein levels in neuroblastoma tumour tissue relative to ACTIN (average 
of two experiments), expressed as a ratio of the level in fetal adrenal (FA; black bar). (E,F) Kaplan–Meier 
survival curves (E), relapse-free survival; (F) overall survival) taken from the dataset of NB patients in C and D 
for whom survival data were available. >FA, tumours with high level of GATA3 protein expression (greater than 
FA); <FA, NB patients with low level of GATA3 protein expression (less than FA). p values from log-rank test.
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when GATA3 was knocked-down (Supplementary Fig. S7), it seems likely that the major mechanism by which 
GATA3 affects neuroblastoma development may be via its effects on cellular proliferation and death (Fig. 5 and 
Supplementary Fig. S4), rather than by affecting cellular differentiation.
Two recent papers have delineated super-enhancer-associated transcriptional circuits that divide neuroblas-
toma cells into two distinct differentiation states55,56; corresponding to undifferentiated mesenchymal cells (MES), 
as found in hNCC, and a sympathetic adrenergic identity (ADRN), in which GATA3 plays a critical role as a mas-
ter transcription factor55,56. Neuroblastomas contain mixtures of these two cell types, but with the majority being 
highly enriched in adrenergic cells, leading to high GATA3 expression, as we have observed (Fig. 4).
Our genome-wide DNA methylation study compared hNCC (mesenchymal differentiation) to neuroblastoma 
cell lines, which mostly have a predominately adrenergic state55,56. Hierarchical clustering of this data demon-
strates the ability of DNA methylation to discriminate between cell lines representing these different lineages 
(Supplementary Fig. S8A). Interestingly, this analysis showed that SK-N-AS clusters separately from the three 
other neuroblastoma cell lines, which agrees with the super-enhancer profiling, which places SK-N-AS as being 
intermediate between the ADRN and mesenchymal MES signatures55,56.
We also showed that adrenergic (ADRN) signature genes were more highly methylated in hNCC than were 
mesenchymal (MES) signature genes56 (Supplementary Fig. S8B). Thus, distinct patterns of DNA methylation are 
associated with alternate differentiation states, suggesting that epigenetic modifications may play an important 
role in defining or stabilising cell identity in neuroblastoma.
Among neuroblastoma cell lines, the S-type cells GI-ME-N and SH-EP are in the mesenchymal differentiation 
pathway, like hNCC cell lines55,56. Interestingly, our results identified GI-ME-N and SH-EP as the only two neu-
roblastoma cell lines that had GATA3 DNA methylation, like hNCC, with corresponding low levels of expression 
of GATA3 protein (Fig. 3). Therefore, our results identify DNA methylation of GATA3 as a characteristic of the 
mesenchymal hNCC-like differentiation pathway, with loss of GATA3 methylation in neuroblastoma cell lines 
and tumours, which contain mainly adrenergic cells. However, we found that knock-down of GATA3 did not alter 
the differentiation status of the three neuroblastoma cell lines tested (Supplementary Fig. S7). This suggests that 
Figure 5. GATA3 biological functions. Growth of IMR32 neuroblastoma cell line after transfection with non-
targeting siRNA (siNEG), or GATA3 siRNAs (si-GATA3-1 and si-GATA3-2). (A) Western Blot of GATA3, 
cleaved PARP (c-PARP) and CCND1 protein expression (representative of three experiments), with ACTIN 
as a loading control. Uncropped blots are shown in Supplementary Fig. S12. (B) GATA3 and CCND1 RNA 
expression assayed by QPCR expressed relative to siNEG controls. Mean ± S.E.M of three experiments, 
*p < 0.05; **p < 0.01, paired t test. (C) Attached cell counts expressed relative to siNEG controls. Mean ± 
S.E.M of three experiments, *p < 0.05, paired t test. (D) Dead cell counts (floating cells that were trypan blue 
permeable) expressed relative to siNEG control in cells treated caspase 3 inhibitor QVD (+QVD, unfilled bars) 
or with drug solvent (DMSO; -QVD, filled bars). Mean ± S.E.M of three experiments, **p < 0.01, **p < 0.001, t 
test. (E) Western Blot of c-PARP protein expression in transfected cells with (+QVD) or without (-QVD) QVD- 
treatment (representative of three experiments), with ACTIN as a loading control. Uncropped blots are shown 
in Supplementary Fig. S12.
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inactivation of just one of the transcription factors defining the adrenergic phenotype, is insufficient to drive neu-
roblastoma cells towards the mesenchymal phenotype, presumably due to the functional redundancy within the 
complex regulatory network. Our results therefore show that GATA3 is essential for the sustained proliferation of 
adrenergic neuroblastoma cells, but not solely responsible for defining their lineage.
The cellular composition of neuroblastomas does not appear to correspond to clinical outcome directly, 
although epigenetic plasticity may allow interconversion between the cell types, driving drug resistance55,56. 
Others have previously shown a high level of GATA3 expression in neuroblastoma50,57, and suggested that GATA3 
is a useful distinguishing diagnostic marker for neuroblastoma58. Our results showed that a complete absence of 
GATA3 DNA methylation (Fig. 2D,E) and a high level of GATA3 protein expression (Fig. 4E,F), were both indi-
cators of poor prognosis in neuroblastoma. Thus, although the adrenergic composition of neuroblastomas may 
not in itself be sufficient to determine the clinical phenotype of neuroblastomas, we suggest that epigenetic defects 
in GATA3 may deregulate the complex transcriptional networks controlling neuroblastoma and thus influence 
clinical outcomes. Therefore, the GATA3 transcriptional network is a promising target for novel neuroblastoma 
therapies.
Materials and Methods
Cell culture and neuroblastoma tumour samples. Cell lines (Supplementary Table S3) were obtained 
from ECACC, apart from BCH-N-DW, which is a novel neuroblastoma cell line derived from a bone marrow 
biopsy (kind gift from Dr C. McConville, unpublished data). Cell lines were cultured in DMEM/F12-HAM 
medium (Sigma) supplemented with 10% fetal bovine serum, 100U/ml penicillin, 0.1 mg/ml streptomycin, 2mM 
L-glutamine and 1% non-essential amino acids (Sigma) at 37 °C in a 5% CO2 incubator.
Human neural crest cell lines (hNCC) were cultured as described previously59,60. Dorsal root ganglia/sympa-
thetic ganglia cell lines (DRG/SG) were derived from cells growing away from dorsal root and sympathetic gan-
glia with some proximal nerve fascicles still attached, explanted from normal 8.5 to 9.5 gestational week human 
embryos (French Agence de la Biomédecine authorization PSF14-011). Within 18 hours of being explanted, the 
remaining pieces of ganglionic tissue were removed manually, and the cells passed into a new culture dish and 
cultured thereafter in the same medium as used for human neural crest cells (hNCC)60 (Etchevers, unpublished). 
DRG/SG lines expressed sympathetic adrenergic markers DBH and MYCN to a higher level than lines derived 
from dorsal root ganglia alone (DRG; Supplementary Fig. S9).
Neuroblastoma tumour samples (Supplementary Table S4) were obtained from Bristol Children’s hospital with 
informed consent (from parent and/or legal guardian for children less than 18 years of age) and with appropriate 
ethical approval (E5797; South West – Central Bristol Research Ethics Committee (UK)). All methods were per-
formed in accordance with the relevant guidelines and regulations, including those specified in the UK Human 
Tissue Act 2004.
Cell counts. For cell viability and determining concentration, Trypan Blue stain (0.4%; Sigma) was mixed 
with cells in a ratio 1/1 before being counted by a Countess cell counter (Invitrogen). Dead cells were assayed by 
counting the number floating (unattached) cells that were trypan blue permeable.
Flow cytometry and cell cycle analysis. Cells were removed from flasks with trypsin, pelleted by cen-
trifugation and fixed in 70% ethanol at −20 °C for 24 hours. They were then treated with RNAase (Qiagen) 
and stained with 50 μg/ml Propidium iodide (Sigma) and incubated at 37 °C for 15 min in the dark. Stained 
cells were analysed using LSR Fortessa X20 (BD Biosciences) using FACS DIVA8 software (Becton-Dickinson 
Immunocytometry Systems) and at least 10,000 events were collected. Cells cycle analysis was performed using 
Flow Jo software V10.
5-Aza-2′-deoxycytidine treatment. Cell lines were incubated in medium containing 2 µM 
5-aza-2′-deoxycytidine (AZA; Sigma) for up to 6 days, with a medium change every three days. Control cultures 
received equivalent volumes of drug solvent (DMSO).
Quinolyl-valyl-O-methylaspartyl-[2,6-difluorophenoxy]-methyl ketone treatment. Cell lines 
were incubated in medium containing 10 µM quinolyl-valyl-O-methylaspartyl-[2,6-difluorophenoxy]-methyl 
ketone (QVD; Sigma) for up to three days. Control cultures received equivalent volumes of drug solvent (DMSO).
GATA3 transient silencing. Cells were transfected with siRNAs (50 nM) against GATA3, or a non-targeting 
siRNA negative control (Supplementary Table S5; all synthesised by Sigma), using Lipofectamine 2000 transfec-
tion reagent (Invitrogen) and harvested after 72 hrs.
Pyrosequencing assay of GATA3 DNA methylation. DNA was bisulfite converted (EZ DNA 
Methylation Gold kit; Zymo Research), amplified with biotinylated primers (Qiagen) using a Pyromark PCR kit 
(Qiagen) and pyrosequenced on a PyroMark Q96 instrument (Qiagen).
Pyrosequencing assay 01 for GATA3 was PM00042273 (Qiagen); sequence analysed TTAATYGYGAGTATT 
AAGTYGGATTGGTYGGGGA, and assay 02 was PM00042280 (Qiagen); sequence analysed GATGTTTTTTAA 
TTGGGTYGTTTAATAAYGGGA.
RNA extraction, cDNA synthesis and RT-PCR. Total RNA was extracted with a RNeasy kit (Qiagen), 
DNase treated with TURBO DNA-free (Ambion) and cDNA synthesized using the Thermoscript RT-PCR system 
(Invitrogen). gene-specific primers (Supplementary Table S6) were used for QPCR (QuantiTect SYBR Green; 
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Qiagen) on an MX3000P real-time PCR machine (Stratagene), normalising the amount of target gene to the 
endogenous level of TBP. Some assays were normalised relative to expression in Human universal RNA (Agilent).
Protein extraction and western blotting. Cultured cells were washed with ice-cold PBS and lysed in 
cell lysis buffer (Cell Signaling), with complete mini inhibitors (Roche) for 10 min on ice, and then sonicated for 
5 min at high intermittent pulses (30/30) (Diagenode, Bioruptor). Neuroblastoma tumour samples were homog-
enised in cell lysis buffer, then processed as for cultured cells. Samples were centrifuged for 10 min at 10,000 g 
at 4 °C to remove any cell debris and typically 25 µg proteins were separated on SDS-polyacrylamide gels and 
analysed by Western blotting. Fetal adrenal protein was from Biochain. Primary antibodies were against GATA3 
(Rabbit monoclonal, Abcam Ab199428), CCND1 (Rabbit monoclonal, Cell Signaling), cleaved-PARP (c-PARP; 
Rabbit monoclonal, Abcam Ab32064), Beta ACTIN (Mouse monoclonal, Sigma A3854), followed by second-
ary HRP-labelled anti-rabbit (Sigma A6154) or HRP-labelled anti-mouse (Sigma A4416). Detection was with 
Lumiglo chemiluminescent substrate (KPL) and X-ray films were imaged on a flatbed scanner and analysed using 
Image J (http://imagej.nih.gov/ij/).
Data availability
The methyl CpG immunoprecipitation (MCIP) data upon which this study is based, has previously been 
deposited in GEO; accession number GSE71958.
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